FDA Approves Olumiant (Baricitinib) for Severe Alopecia Areata in Adolescents 12 and Older

FDA Approves Olumiant (Baricitinib) for Severe Alopecia Areata in Adolescents 12 and Older

Eli Lilly announced this weekend (Sept 26–27, 2026) that the FDA approved Olumiant (baricitinib), a once-daily oral JAK inhibitor, "to treat pediatric patients 12 years of age and older with severe alopecia areata (AA)" — a label expansion of the first systemic treatment ever approved for the condition (adults, June 2022).

Why it matters. AA is a chronic immune-mediated disease causing unpredictable hair loss; up to 2% of people develop it in their lifetime, and "nearly 40% of cases occur before the age of 20," with early-onset disease often more severe. Adolescents with severe AA previously had no approved systemic option. Lilly's immunology president Adrienne Brown: "Today's approval marks an important milestone for young people living with severe alopecia areata and their families, who have had limited treatment options to date... Expanding Olumiant to patients as young as 12 provides them a much-needed treatment choice."

Safety framing. The pediatric safety profile was consistent with adults¹, but the label carries the class boxed warning for JAK inhibitors: "risk of serious infections, mortality, malignancy, major adverse cardiovascular events (MACE) and thrombosis." More than 33,000 US patients have been prescribed Olumiant since 2017; annual sales run around $1 billion. The drug was discovered by Incyte and licensed to Lilly.